SCIB1 Vaccine May Synergize With Nivo-Ipi Against Melanoma
Source: Cancer Therapy Advisor, April 2024
An investigational vaccine, SCIB1, has demonstrated activity when used in combination with nivolumab and ipilimumab in patients with advanced melanoma, according to research presented at the AACR Annual Meeting 2024.
SCIB1 incorporates CD4 and CD8 epitopes from TRP-2 and gp100 into an antibody framework to allow for targeting of activated dendritic cells, explained study presenter Lindy Durrant, PhD, of Scancell Ltd. and the University of Nottingham in the United Kingdom.
Dr Durrant and colleagues conducted the phase 2 SCOPE trial (ClinicalTrials.gov Identifier: NCT04079166) to determine if SCIB1 would demonstrate synergistic activity with immune checkpoint inhibitors.